Heron Therapeutics (HRTX) said Tuesday it reached a settlement agreement with Viatris' (VTRS) Mylan Pharmaceuticals to resolve patent litigation over the Cinvanti and Aponvie injectable emulsions.
Under the deal, Heron granted Mylan a license to market generic versions of Cinvanti and Aponvie in the US beginning June 1, 2032.
In connection with the settlement, Heron and Mylan will ask the US District Court for the District of Delaware to dismiss the pending litigations, Heron said.
The company said it initiated the litigations in response to what it described as Mylan's abbreviated new drug applications seeking the US Food and Drug Administration's approval of generic Cinvanti and Aponvie versions before the expiration of the Heron patents in 2035.
Heron shares rose nearly 14% in recent trading.
Price: 2.43, Change: +0.30, Percent Change: +13.85
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。